title: Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life.
abstract: OBJECTIVE
  To describe the anatomical and functional outcomes in patients with exudative age-related macular degeneration (AMD) undergoing ranibizumab therapy in real-life practice.
  
  
  METHODS
  This is a retrospective analysis of patients with exudative AMD treated with ranibizumab. Visual acuity (VA) and optic coherence tomography characteristics at baseline and at the end of the follow-up, clinical forms of the disease, delay between diagnosis and treatment as well as the number of follow-up visits and of intravitreal injections were collected.
  
  
  RESULTS
  One hundred and seventy-nine patients (220 eyes) were followed up during a mean of 24 months. The mean delay between diagnosis and treatment was 20.3 days (SD ±16.8). VA stabilization was observed in 46.4% of eyes, 21.7% of eyes gained ≥15 ETDRS (Early Treatment Diabetic Retinopathy Study) letters and 31.9% lost ≥15 ETDRS letters. The mean central retinal thickness decreased from 380.6 μm at baseline to 295.6 µm at the final examination. A lower baseline VA score was associated with a greater gain of letters (OR 1.04, 95% CI 1.02-1.06; p < 0.001).
  
  
  CONCLUSIONS
  Shortening the delays in diagnosis appears to be a key point in real-life situations.
authors.affiliation: Department of Ophthalmology, Poitiers University Hospital, Poitiers, France.
authors.forename: Agathe
authors.initials: A
authors.lastname: Cazet-Supervielle
authors.forename: Julien
authors.initials: J
authors.lastname: Gozlan
authors.forename: Séverin
authors.initials: S
authors.lastname: Cabasson
authors.forename: Michèle
authors.initials: M
authors.lastname: Boissonnot
authors.forename: Hélène
authors.initials: H
authors.lastname: Manic
authors.forename: Nicolas
authors.initials: N
authors.lastname: Leveziel
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab